LakeShore Biopharma Co., Ltd (LSB) - Total Liabilities
Based on the latest financial reports, LakeShore Biopharma Co., Ltd (LSB) has total liabilities worth $867.91 Million USD as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See LSB working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
LakeShore Biopharma Co., Ltd - Total Liabilities Trend (2021–2025)
This chart illustrates how LakeShore Biopharma Co., Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see LSB total assets.
LakeShore Biopharma Co., Ltd Competitors by Total Liabilities
The table below lists competitors of LakeShore Biopharma Co., Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Cadence Opportunities Fund Ltd
AU:CDO
|
Australia | AU$13.30 Million |
|
Shenzhen Textile Holdings Co Ltd
SHE:200045
|
China | HK$1.06 Billion |
|
Mawson Infrastructure Group Inc
NASDAQ:MIGI
|
USA | $60.56 Million |
|
BCB Bhd
KLSE:6602
|
Malaysia | RM719.51 Million |
|
Pennon Group Plc
LSE:PNN
|
UK | GBX6.07 Billion |
|
Metal Energy Corp
V:MERG
|
Canada | CA$4.10 Million |
|
Perdana Gapura Prima Tbk
JK:GPRA
|
Indonesia | Rp499.16 Billion |
|
Carelabs Co.Ltd
KQ:263700
|
Korea | ₩26.83 Billion |
Liability Composition Analysis (2021–2025)
This chart breaks down LakeShore Biopharma Co., Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See LSB equity to assets ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.02 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.74 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.63 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how LakeShore Biopharma Co., Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for LakeShore Biopharma Co., Ltd (2021–2025)
The table below shows the annual total liabilities of LakeShore Biopharma Co., Ltd from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | $867.91 Million | -6.46% |
| 2024-03-31 | $927.82 Million | -6.40% |
| 2023-03-31 | $991.30 Million | +4770.78% |
| 2022-03-31 | $20.35 Million | +28970.13% |
| 2021-03-31 | $70.01K | -- |
About LakeShore Biopharma Co., Ltd
LakeShore Biopharma Co., Ltd, a biopharmaceutical company, discovers, develops, manufactures, commercializes, and sells vaccines and therapeutic biologics for infectious diseases and cancer. Its product pipeline includes YSJA, a conventional rabies vaccine, which is in marketed stage; PIKA, a rabies vaccine, which is in phase I/III and preclinical trials for the treatment of rabies virus; PIKA YS… Read more